Roivant Sciences Ltd. Common Shares (ROIV)

Price$28.58

Value ScoreD

Growth ScoreF

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)29.41%

Price vs S&P 500 (4W)0.08%

VGM Score37.01

Market Capitalization$20.56B

All Metrics

Book Value / Share (Quarterly)$6.28

P/TBV (Annual)1.44x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-48.73%

Cash Flow / Share (Quarterly)$-1.05

Price vs S&P 500 (YTD)23.55%

Gross Margin (TTM)84.44%

Net Profit Margin (TTM)-3629.19%

EPS (TTM)$-0.45

10-Day Avg Trading Volume5.56M

EPS Excl Extra (TTM)$-0.45

Revenue Growth (5Y)-19.08%

EPS (Annual)$-0.43

ROI (Annual)-6.62%

Gross Margin (Annual)84.44%

Net Profit Margin (5Y Avg)-782.33%

Cash / Share (Quarterly)$5.96

Revenue Growth QoQ (YoY)-66.71%

ROA (Last FY)-5.25%

Revenue Growth TTM (YoY)-89.16%

EBITD / Share (TTM)$-0.72

ROE (5Y Avg)-15.12%

Operating Margin (TTM)-6102.19%

Cash Flow / Share (Annual)$-1.05

P/B Ratio4.54x

P/B Ratio (Quarterly)4.38x

Net Income / Employee (Annual)$-399,700

EV / Revenue (TTM)2316.89x

Net Interest Coverage (TTM)-72.78x

ROA (TTM)-5.70%

EV / EBITDA (TTM)4.36x

EPS Incl Extra (Annual)$-0.43

Current Ratio (Annual)18.37x

Quick Ratio (Quarterly)18.37x

3-Month Avg Trading Volume6.08M

52-Week Price Return155.18%

Revenue / Employee (TTM)$11,000

Tangible BV / Share (Quarterly)$7.17

P/S Ratio (Annual)2488.71x

Asset Turnover (Annual)0.00x

52-Week High$32.79

Operating Margin (5Y Avg)-2020.10%

EPS Excl Extra (Annual)$-0.43

CapEx CAGR (5Y)7.19%

26-Week Price Return37.34%

Quick Ratio (Annual)18.37x

13-Week Price Return-3.84%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)18.37x

Enterprise Value$19.14B

Revenue / Share Growth (5Y)-19.31%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$11,000

Pretax Margin (Annual)-3203.12%

Cash / Share (Annual)$5.96

3-Month Return Std Dev43.45%

Gross Margin (5Y Avg)73.72%

Net Income / Employee (TTM)$-399,700

ROE (Last FY)-6.62%

Net Interest Coverage (Annual)-7.02x

EPS Basic Excl Extra (Annual)$-0.43

Receivables Turnover (TTM)4.67x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.45

Receivables Turnover (Annual)2.97x

ROI (TTM)-6.85%

P/S Ratio (TTM)2488.71x

Pretax Margin (5Y Avg)-1111.67%

Revenue / Share (Annual)$0.01

Tangible BV / Share (Annual)$7.23

Price vs S&P 500 (52W)130.81%

Year-to-Date Return31.71%

5-Day Price Return-1.75%

EPS Normalized (Annual)$-0.43

ROA (5Y Avg)-4.63%

Net Profit Margin (Annual)-3629.19%

Month-to-Date Return-4.70%

Cash Flow / Share (TTM)$-1.62

EBITD / Share (Annual)$-0.72

Operating Margin (Annual)-6102.19%

LT Debt / Equity (Annual)0.07x

ROI (5Y Avg)-10.32%

LT Debt / Equity (Quarterly)0.06x

EPS Basic Excl Extra (TTM)$-0.45

P/TBV (Quarterly)1.51x

P/B Ratio (Annual)4.38x

Inventory Turnover (TTM)0.61x

Pretax Margin (TTM)-3203.12%

Book Value / Share (Annual)$6.28

Price vs S&P 500 (13W)-12.09%

Beta1.15x

Revenue / Share (TTM)$0.01

ROE (TTM)-6.85%

52-Week Low$10.71

vGradeD

gGradeF

mGradeB

vgmGradeD

Show chart for

Earnings Surprise History

Q4 26-0.58est. -0.35

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

4.28

4.32

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$28.58
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Roivant Sciences is a commercial-stage biopharmaceutical company with VTAMA (tapinarof), an approved treatment for plaque psoriasis, as its lead marketed product. The company maintains a pipeline of drug candidates across development stages including Batoclimab, Brepocitinib, Namilumab, and IMVT-1402. Roivant also incubates discovery-stage biotech companies and health technology platforms adjacent to its core pharmaceutical business.